Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.38 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | FASN | P49327 | 3/20 | 0.37 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.37 |
| ▸ | CCNC | P24863 | 5/20 | 0.36 |
| ▸ | CDK8 | P49336 | 5/20 | 0.36 |
| ▸ | CDK19 | Q9BWU1 | 3/20 | 0.36 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084335 | 0.91 | RXRA (0.42) | L3MBTL1RXRARXRBRXRG | |
| SCHEMBL4084768 | 0.89 | JAK2 (0.40) | RXRARXRBRXRG | |
| SCHEMBL4080192 | 0.85 | RXRA (0.39) | SCN7AKCNH2RXRARXRBRXRG | |
| SCHEMBL5378043 | 0.85 | RXRA (0.38) | KDM1ASCN7ARXRARXRBRXRG | |
| SCHEMBL4084834 | 0.85 | EGLN1 (0.40) | FASNL3MBTL1CNR2RXRARXRB | |
| SCHEMBL4089930 | 0.85 | RXRA (0.38) | RXRARXRBRXRG | |
| SCHEMBL4083268 | 0.83 | RXRA (0.37) | SCN7AKCNH2RXRARXRBRXRG | |
| SCHEMBL4080434 | 0.83 | RXRA (0.37) | L3MBTL1RXRARXRBRXRG | |
| SCHEMBL4094652 | 0.82 | RAB9A (0.37) | KDM1ARXRARXRBRXRG | |
| SCHEMBL4088673 | 0.81 | CMKLR1 (0.37) | KCNH2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713773-A2 | N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-10-25 | — | — | EP | claimed |
| WO-2005074513-A2 | N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-08-18 | — | — | WO | claimed |
| EP-2065383-A1 | Indazole compounds and methods of use thereof as protein kinase inhibitors | Signal Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| EP-1713773-A2 | N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-10-25 | — | — | EP | disclosed |
| EP-1692128-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | Signal Pharmaceuticals LLC (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| WO-2005074513-A2 | N-BENZYL-3,4-DIHYROXYPYRIDINE-2-CARBOXAMIDE AND N-BENZYL-2,3-DIHYDROXYPYRIDINE-4-CARBOXAMIDE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | CDK1 159/4885KDM1A 3862/4885EGLN2 3009/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | CDK1 153/4885KDM1A 3917/4885EGLN2 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.